STAT July 29, 2022
David Reese and Kári Stefánsson

Precision medicine — tailoring a treatment to an individual’s disease — requires understanding the individual’s biological characteristics. Although medicine and biotech are making significant progress in this area, they have historically been limited by few genetic samples and insights from patients of diverse backgrounds, particularly in therapeutic categories including cardiometabolism, inflammation, and other diseases with a disproportionate incidence among underrepresented racial and ethnic groups.

More than 80% of genomics studies have been conducted in people of European descent. If this imbalance is not fully addressed, a lack of diverse DNA sampling has the potential to hold back the pace of drug discovery and the development of, and more equitable access to, the promise of precision medicine.

As scientists with more...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Equity/SDOH, Healthcare System, Patient / Consumer, Pharma / Biotech, Precision Medicine, Provider
Advancing Equitable Access to Elevate Value-Based Cancer Care
Hospices Have Long Road Ahead on Improving Health Equity
Election Implications for Telehealth, Health Equity, AI and Life Sciences
Podcast: Washington Housing Conservancy Shapes Health via Housing Reform
Alzheimer Disease Treatment Can Improve Population Health and Health Equity

Share This Article